Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

 
• By Alaric DeArment
Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

More from Clinical Trials

More from R&D